NCT01194986View on ClinicalTrials.gov

Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Brain Distribution of [11C]AZ12807110 and AZD5213
Interventions
OTHER

[11C]AZ12807110

Radioligand

DRUG

AZD5213

Trial Locations (1)

Unknown

Research Site, Uppsala

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY